['atopic dermatitis']
['placebos']

        Inclusion Criteria:

          -  Male or female, 18 years or older.

          -  Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ≥1 year
             before the screening visit .

          -  Eczema Area and Severity Index (EASI) score ≥16 at the screening and the baseline
             visit.

          -  Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the screening and
             the baseline visit.

          -  ≥10% body surface area (BSA) of AD involvement at the screening and the baseline
             visit.

        Exclusion Criteria:

          -  Treatment with any of the following agents within 4 weeks prior to the baseline visit:

          -  Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids,
             cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine,
             methotrexate, etc.)

          -  Phototherapy and photochemotherapy (PUVA) for AD.

          -  Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)
             within 1 week prior to the baseline visit.

          -  Treatment with:

          -  An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is
             longer, prior to the baseline visit.

          -  Dupilumab within 3 months prior to baseline visit.

          -  Cell-depleting biologics, including rituximab, within 6 months prior to the baseline
             visit.

          -  Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit
             (whichever is longer).

          -  Use of prescription moisturizers within 7 days of the baseline visit.
      